The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: A meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Yin, An An ^a   Zhang, Lu Hua ^a   Cheng, Jin Xiang ^a   Dong, Yu ^b   Liu, Bo Lin ^a   Han, Ning ^a   Zhang, Xiang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

AGE; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DNA METHYLATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; MGMT GENE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SYSTEMATIC REVIEW;

AGED; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS; TUMOR SUPPRESSOR PROTEINS;

EID: 84897971058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085102     Document Type: Article

References (43)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
2. Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, et al. (2012) Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. DOI: 10.1016/j.ctrv.2012.05.008.
3. Kita D, Ciernik IF, Vaccarella S, Franceschi S, Kleihues P, et al. (2009) Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology 33: 17-22.
4. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE (2008) Patterns of care in elderly glioblastoma patients. Ann Neurol 64: 628-634.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. (Pubitemid 40349502)
7. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, et al. (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neurooncologia (GICNO). Br J Cancer 95: 1155-1160. (Pubitemid 44658477)
8. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, et al. (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101: 124-131.
9. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, et al. (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27: 5743-5750.
10. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, et al. (2010) Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 77: 670-676.
11. Siu LL (2007) Clinical trials in the elderly - a concept comes of age. N Engl J Med 356: 1575-1576.
12. Macdonald DR, Cascino TL, Schold SJ, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280. (Pubitemid 20195640)
13. Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical-epidemiology/ oxford.asp. Accessed 2013 Jan 5.
14. Yin AA, Zhang LH, Cheng JX, Dong Y, Liu BL, et al. (2013) Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. Plos ONE 8(9): e74242.
15. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Available at http://handbook.cochrane.org/. Accessed 2013 Jan 5.
16. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 9: e1001216.
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
18. Petretta M, Pirozzi F, Sasso L, Paglia A, Bonaduce D (2011) Review and metaanalysis of the frequency of familial dilated cardiomyopathy. Am J Cardiol 108: 1171-1176.
19. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
20. Lombardi G, Bellu L, Berti F, Farina P, Galuppo S, et al. (2013) Efficacy and safety of radiotherapy (RT) plus temozolomide (TMZ) in elderly patients (EP) with glioblastoma (GBM). Journal of Clinical Oncology 15: 1.
21. Mishima K, Adachi J, Suzuki T, Wakiya K, Yanagisawa T, et al. (2010) Radiotherapy plus concomitant and adjuvant themozolomide for glioblastoma in elderly patients. Neuro Oncol 12 (suppl.3): i46.
22. Philippe M, Isabelle N, Olivier C, Frederic F, Stephane F, et al. (2011) Prognostic significance of mgmt promoter methylation status in elderly patients with newly diagnosed glioblastoma treated with BCNU wafer implantation: A prospective patient cohort. Neuro-Oncology SUPPL.3: i56.
23. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, et al. (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131: 1342-1350.
24. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, et al. (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13: 916-926.
25. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, et al. (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13: 707-715.
26. Gallego PJ, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, et al. (2011) Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 29: 3050-3055.
27. Abhinav K, Aquilina K, Gbejuade H, La M, Hopkins K, et al. (2013) A pilot study of glioblastoma multiforme in elderly patients: Treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival. Clin Neurol Neurosurg. DOI: 10.1016/j.clineuro.2012.12.023.
28. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, et al. (2009) Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 73: 1509-1510.
29. Piccirilli M, Bistazzoni S, Gagliardi FM, Landi A, Santoro A, et al. (2006) Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori 92: 98-103. (Pubitemid 43835967)
30. Sijben AE, McIntyre JB, Roldan GB, Easaw JC, Yan E, et al. (2008) Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 89: 97-103.
31. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, et al. (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115: 3512-3518.
32. Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, et al. (2011) Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 102: 311-316.
33. Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, et al. (2012) Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83: 93-99.
34. Fiorentino A, Balducci M, De Bonis P, Chiesa S, De Filippo L, et al. (2013) Can Elderly Patients With Newly Diagnosed Glioblastoma be Enrolled in Radiochemotherapy Trials? Am J Clin Oncol.
35. Franceschi E, Tosoni A, Morandi L, Cerasoli S, Lanza G, et al. (2013) A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology; PERNO) in newly diagnosed GBM patients (pts): Outcome analysis and correlations with MGMT methylation status in the elderly population. Journal of Clinical Oncology 15: 1.
36. Italiano A (2011) Prognostic or predictive? It's time to get back to definitions!. J Clin Oncol 29: 4718, 4718-4719.
37. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, et al. (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39-51.
38. Yin AA, Cheng JX, Zhang X, Liu BL (2013) The treatment of glioblastomas: A systematic update on clinical Phase III trials. Crit Rev Oncol Hematol 87: 265-282
39. Berghoff AS, Preusser M (2012) Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients - yes, but how? Clin Neuropathol 31: 405-408.
40. Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, et al. (2012) Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 14 Suppl 4: v100-v108.
41. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, et al. (2012) Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One 7: e33449.
42. Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P (2007) Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res 67: 4545-4549.
43. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, et al. (2008) Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10: 332-337. (Pubitemid 352019119)